CITY-OF-ESPOO
At the three-day conference that brings the management of European cities together, the topics discussed include the inclusion of young people, co-creation and cities’ leadership in the work against climate change. The theme of the annual conference, An Era of New Beginnings, consists of three parts, Dream, Act and Lead, through which these topics are studied. The conference attendees include city leadership from Oslo, Rotterdam, Helsinki, Brussels, Stockholm and Munich, among other cities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005019/en/
On Friday, one of the keynote speakers will be Executive Vice-President of the European Commission Frans Timmermans , who will introduce the discussion on climate-neutral cities.
“Cities play a key role in the progress towards the EU’s climate goals and building a sustainable future. The annual conference also strengthens the dialogue between cities and the European Commission. However, achieving the goals will be impossible if cities cannot extensively involve operators from all sectors of society. Co-creation and cooperation between the public and private sector are some of the overarching themes of the conference, in addition to climate leadership and young people’s inclusion,” says Milla Ovaska , Head of International Affairs at the City of Espoo.
As a part of the conference and the European Year of Youth, Espoo is organising the Future Mentors programme in which young people living in European cities engage in dialogue with the policymakers of their cities. This is called reverse mentoring.
“We wanted to provide young people with an opportunity to voice their dreams, wishes and concerns about the future of their home city. The decisions that we are making now will have long-term influence, and young people will be the ones living in the future we create. We would like the programme to encourage policymakers to engage in dialogue and give space to new ways of thinking,” says Marianne Julkunen , Partnership Coordinator.
Eurocities Awards to best practices of resident inclusion
On the evening of Thursday 9 June, the conference programme includes the Eurocities Awards ceremony , which showcases the member cities’ projects that have succeeded best in involving their residents and influencing their quality of life. This year’s awards will be given in three categories: ‘Future generations transforming the cities,’ ‘Skills and competences for the future’ and ‘Scalable solutions for positive climate impact.’ The winners will be selected by a five-person jury.
Representatives of the media are cordially invited to attend the annual Eurocities conference on-site at Espoo, Finland. The conference is also available virtually on its website .
#Eurocities2022
#FutureMentors2022
The conference has been created in collaboration with various organisations, all relevant to building future-proof cities and societies. The main partners are Aalto University and VTT. You can find all partners at: eurocities2022.eu/partners .
Eurocities is the key network of European cities for Espoo. Eurocities supervises interests at the level of the EU, generates information about the EU’s funding application rounds and EU legislation, and functions as a peer learning platform for its member cities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
